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Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are
essential for making the diagnosis, and by additional tests to clarify the category of pulmonary
hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all
guidelines the algorithm can be modified according to specific clinical circumstances. Most
patients are diagnosed as the result of an evaluation of symptoms, whereas others are
diagnosed during screening of asymptomatic populations at risk. Right heart catheterization
(RHC) must be performed in patients with suspected PH to establish the diagnosis and
document pulmonary hemodynamics. Before initiation of medical therapy, assessment of
acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy
for an individual patient. An acute response is generally defined as a decrease in mean
pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure
decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After
PAH is diagnosed, disease severity should be assessed in order to accurately determine
risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include
functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right
ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin
levels. Repeating these tests serially on treatment is useful for monitoring the response to a
given therapy. Close follow-up at a center specializing in management of PH is recom-
mended, with careful periodic reassessment and adjustment of therapy. (J Am Coll Cardiol
2004;43:40S–47S) © 2004 by the American College of Cardiology Foundationg
w
s
h
p
l
n
s
d
d
a
I
h
i
d
e
M
d
o
v
fi
a
m
H
n
m
the diagnosis of pulmonary hypertension (PH) involves
wo stages: detection (determining the cause of a patient’s
ymptoms, or to detect the presence of pulmonary arterial
ypertension [PAH] in a high-risk patient) and character-
zation (determining the specific clinical context of the PH,
ncluding causal factors, associated diseases or substrates,
emodynamic perturbations and their localization, and
equelae).
ETECTION
ymptom evaluation. Symptoms that suggest PH are
xertional dyspnea, fatigue or weakness, angina, syncope,
eripheral edema, and abdominal distension (Fig. 1). Exer-
ional intolerance is quantitated with the World Health
rganization (WHO) classification (Table 1).
creening. Periodic assessment of patients with an under-
ying predisposition may be warranted to introduce therapy
t an early stage, or to initiate more aggressive surveillance
o detect progression. Screening for the presence of PAH
sing Doppler echocardiography is advisable when risk is
ufficiently high to justify the expense (i.e., when diagnosis
ould lead to further evaluation and/or change in manage-
ent). This currently includes individuals with: 1) a known
From the *Columbia University College of Physicians and Surgeons, New York,
ew York; †Mayo Clinic, Rochester, Minnesota; ‡Institute of Tuberculosis and
ung Diseases, Warsaw, Poland; §Hoˆpital Antoine Be´cle`re, Clamart, France;
Medical Clinic II, University Clinic, Giessen, Germany; and ¶Mater Misericordiae
ospital, University College, Dublin, Ireland.fiManuscript received November 26, 2003; accepted February 3, 2004.enetic-mutation–associated PAH or a first-degree relative
ith idiopathic pulmonary arterial hypertension (IPAH); 2)
cleroderma spectrum of disease; 3) patients with congenital
eart disease and systemic-to-pulmonary shunts; or 4)
ortal hypertension undergoing evaluation for orthotopic
iver transplantation (1). Other potential PAH substrates do
ot warrant routine screening (e.g., previous use of appetite
uppressant, HIV infection, other connective tissue disor-
ers, obstructive pulmonary disease, or high-altitude resi-
ence because of the infrequency and/or low likelihood of
ltering treatment at a presymptomatic stage).
ncidental discovery. The clinical significance and natural
istory of asymptomatic or mild PAH is unclear; thus, the
mplications for further assessment and/or treatment when
iscovered incidentally, as a result of screening or during
valuation of nonspecific symptoms, remain uncertain.
oreover, the criterion of clinically significant PH when
etected under these circumstances by Doppler echocardi-
graphy, which in itself is an isolated estimate of right
entricular systolic pressure (RVSP), is not precisely de-
ned. Commonly used definitions of PH are a pulmonary
rtery systolic pressure (PASP) 35 mm Hg or mean 25
m Hg at rest or mean 30 mm Hg with exercise.
owever, PASP 40 mm Hg is present in 6% of otherwise
ormal individuals older than 50 years and 5% with a body
ass index (BMI) 30 kg/m2 (2).
In general, any degree of PH should prompt an attempt
o define or exclude possible causes, because it may be the
rst evidence of a modifiable substrate. However, the
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June 16, 2004:40S–47S Evaluation of Pulmonary Arterial Hypertensioneverity of PH and the reliability of the measurement should
emper the aggressiveness of the evaluation. Confirmation
y right heart catheterization (RHC) is warranted before
mbarking on extensive evaluation for an underlying cause
r considerations of prognosis or treatment.
etection assessment. Components of assessment to de-
ect PAH include the physical examination (e.g., left
arasternal lift, accentuated pulmonary component of S2,
ansystolic murmur of tricuspid regurgitation, diastolic
urmur of pulmonary insufficiency, right ventricular S3,
ugular vein distension, hepatomegaly, peripheral edema,
scites, cool extremities), chest X-ray, electrocardiogram
ECG), and Doppler echocardiogram. Findings of central
ulmonary arterial and/or right ventricular enlargement on
hest X-ray suggest the presence of PAH. Additional clues
o possible associated diseases should be considered, such as
ulmonary venous hypertension—for example, septal lines
nd pleural effusions (pulmonary venous hypertension due
o left heart filling abnormality, pulmonary veno-occlusive
isease, pulmonary capillary hemangiomatosis); hyperinfla-
ion (chronic obstructive pulmonary disease); or kyphosis
restrictive pulmonary disease). Marked asymmetry of the
nlarged central pulmonary arteries may be a clue to chronic
hromboembolic disease.
The ECG may provide suggestive or supportive evidence
f PAH by demonstrating right ventricular hypertrophy and
train, and right atrial dilation. Right ventricular hypertro-
hy on ECG is present in 87% and right axis deviation in
9% of patients with IPAH (3). The ECG has inadequate
ensitivity (55%) and specificity (70%) to be a screening tool
or detecting significant PAH (4).
Transthoracic Doppler echocardiography (TTE) estimates
ASP and can provide additional information about the
ause and consequences of PH. The PASP is equivalent to
VSP in the absence of pulmonary outflow obstruction.
he RVSP is approximated by measurement of the systolic
egurgitant tricuspid flow velocity v and an estimate of right
trial pressure (RAP) applied in the formula: RVSP  4v2
Abbreviations and Acronyms
BMI  body mass index
CI  cardiac index
CTEPH  chronic thromboembolic pulmonary
hypertension
ECG  electrocardiogram
IPAH  idiopathic pulmonary arterial hypertension
PA  pulmonary artery
PAH  pulmonary arterial hypertension
PASP  pulmonary artery systolic pressure
PH  pulmonary hypertension
RAP  right atrial pressure
RHC  right heart catheterization
RVSP  right ventricular systolic pressure
TTE  transthoracic Doppler echocardiography
V˙/Q˙  ventilation–perfusionRAP. The RAP is either a standardized value, or anstimated value from characteristics of the inferior vena cava
5) or from jugular venous distension. Tricuspid regurgitant
ets can be assessed in 39% to 86% of patients. Careful
oppler examination by experienced sonographers yields
uantifiable tricuspid regurgitant signals in 74% of cases (6).
ost studies report a high correlation (0.57 to 0.93)
etween TTE and RHC measurements of PASP (7).
eported sensitivity of TTE-estimated PASP for detecting
AH ranges from 0.79 to 1.00 (7–9) and specificity from
.60 to 0.98. However, these figures are strongly influenced
y the value used to define PH.
The range of RVSP among healthy controls has been well
haracterized. Among a broad population of male and
emale subjects ranging from 1 to 89 years of age, RVSP was
eported as 28  5 mm Hg (range 15 to 57 mm Hg). The
VSP increases with age and BMI (2). Athletically condi-
ioned men also have higher resting RVSP. Defining the
ormal distribution of RVSP does not ipso facto define the
oint at which an elevated RVSP is clinically important or
redictive of future consequences.
igure 1. Guidelines for evaluating pulmonary hypertension. Abbrevia-
ions: BNP brain natriuretic peptide; CBC complete blood count; CT
computerized tomography; CTD  connective tissue disease; EBCT 
lectron beam computerized tomography; HIV  human immunodefi-
iency virus; HRCT  high-resolution computerized tomography; LFTs
liver function tests; PH  pulmonary hypertension; RHC  right heart
atheterization; SaO2  systemic arterial oxygen saturation; TEE 
ransesophageal echocardiography; VD  vasodilator; V˙/Q˙  ventilation/
erfusion.Mild PH is defined as a PASP of approximately 36 to 50
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Evaluation of Pulmonary Arterial Hypertension June 16, 2004:40S–47Sm Hg or a resting tricuspid reguritant velocity of 2.8 to 3.4
/s. Possible explanations for mildly elevated PASP de-
ected by echocardiography include 1) overestimation of the
VSP in a patient with true normal pulmonary pressure; 2)
erendipitous observation of a rare transient pressure eleva-
ion in an otherwise healthy individual; 3) discovery of
table mild PH, possibly of long duration; or 4) discovery of
arly progressive PH in an individual with PAH. In addi-
ion, pulmonary artery pressure differences may be observed
n different populations and conditions, including age, level
f conditioning, exercise or stress. No clear guidelines are
vailable that delineate normal from pathologic in all
ircumstances.
Pulmonary hemodynamics can also be estimated from the
ulmonary regurgitant Doppler signal, right ventricular
utflow patterns, and time intervals, including pre-ejection
eriod, acceleration and deceleration times, and relaxation
nd contraction times.
HARACTERIZATION: ESSENTIAL TESTS
ertain tests are essential if PH is suspected in order to
haracterize potential substrates, to determine severity and
rognosis accurately, and to select treatment (Fig. 1). The
oppler echocardiogram provides essential information in
ddition to screening, as noted above, including estimation
f baseline and follow-up PASP, estimated pulmonary
ascular resistance, right ventricular size and function,
emiquantitative right atrial size, left ventricular systolic and
iastolic function, presence of prognostically relevant peri-
ardial effusion, morphology and function of all cardiac
alves, as well as patent foramen ovale, and intracardiac or
ntrapulmonary shunts (using “bubble” contrast techniques).
Pulmonary function testing will exclude or characterize the
ontribution of underlying airway or parenchymal disease.
able 1. World Health Organization Classification of
unctional Status of Patients With Pulmonary Hypertension
Class Description
I Patients with pulmonary hypertension in whom there is no
limitation of usual physical activity; ordinary physical
activity does not cause increased dyspnea, fatigue, chest
pain, or presyncope.
II Patients with pulmonary hypertension who have mild
limitation of physical activity. There is no discomfort at
rest, but normal physical activity causes increased
dyspnea, fatigue, chest pain, or presyncope.
III Patients with pulmonary hypertension who have a marked
limitation of physical activity. There is no discomfort at
rest, but less than ordinary activity causes increased
dyspnea, fatigue, chest pain, or presyncope.
IV Patients with pulmonary hypertension who are unable to
perform any physical activity at rest and who may have
signs of right ventricular failure. Dyspnea and/or fatigue
may be present at rest and symptoms are increased by
almost any physical activity.
dapted from Rich S. Primary pulmonary hypertension: executive summary. Evian,
rance: World Health Organization, 1998 (33).lthough obstructive pulmonary disease with hypoxemia cay be confirmed by testing, abnormalities occur in other
ypes of PH. Approximately 20% of patients with chronic
ulmonary embolism have restrictive parameters (i.e., lung
olumes 80% predicted) but may have near normal dif-
using capacity for carbon monoxide (DLCO). The DLCO of
0% of patients with limited systemic sclerosis is below
ormal; a DLCO of 55% of predicted may be associated
ith future development of PAH.
Screening overnight oximetry will exclude significant ob-
tructive sleep apnea/hypopnea.
Ventilation-perfusion (V˙/Q˙) lung scintigraphy is an indis-
ensable component of assessment because chronic throm-
oembolic pulmonary hypertension (CTEPH) is a poten-
ially curable cause of PH. The V˙/Q˙ scans of patients with
hronic pulmonary embolism generally show at least one
egmental-sized or larger perfusion defect. Patients with
H who have normal V˙/Q˙ scans are unlikely to have
hronic pulmonary embolism, and more likely to have
PAH. In three studies (10–12), V˙/Q˙ scanning showed
ensitivity of 90% to 100%, with a specificity of 94% to
00% for distinguishing between IPAH and CTEPH. The
˙ /Q˙ scans tend to correlate poorly with the severity of
bstruction and to underestimate the degree of severity of
arge vessel obstruction. Scans consistent with thromboem-
olism may represent false positives, where the actual
nderlying pathology is pulmonary artery sarcoma, large
essel pulmonary vasculitis, extrinsic vascular compression,
r pulmonary veno-occlusive disease.
Blood tests for evaluation of PAH include antinuclear
ntibody (ANA) titer to screen for connective tissue disease,
IV serology, complete blood count with platelet count,
iver function tests, and antiphospholipid antibodies (lupus
nticoagulant, anticardiolipin antibodies). Although 40% of
atients with IPAH have positive but low ANA titers
1:80 dilutions) (13), patients with a substantially elevated
NA and/or suspicious clinical features require further
erologic assessment and rheumatology consultation.
Assessment of exercise capacity is a key part of the evaluation
f PH. The goals of exercise testing vary under different
linical circumstances, and they determine the specific
esting modality to employ. These objectives include:
earching for alternative or contributory reasons for symp-
oms (e.g., myocardial ischemia); determining maximal
xercise tolerance; characterizing comfortable activity level
functional capacity) of the patient; obtaining predictive
ata; establishing a baseline measure of exercise capacity and
ollowing the response to therapy; assessing the interaction
f the circulatory and ventilatory systems; or attempting to
iscover abnormal pulmonary hemodynamic responses to
xercise before clinically evident PH at rest.
The most commonly used exercise tests for PH are the
-min walk test (6MWT) and cardiopulmonary exercise
esting with gas exchange measurements. Other options
nclude exercise testing in conjunction with noninvasive
oppler echocardiographic assessment of RVSP, and exer-
ise testing in conjunction with RHC.
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June 16, 2004:40S–47S Evaluation of Pulmonary Arterial HypertensionThe 6MWT, developed for evaluation of congestive heart
ailure (14), is predictive of survival in IPAH and also
orrelates inversely with WHO functional status severity,
oderately with baseline cardiac output and total pulmo-
ary resistance (but not mean pulmonary arterial pressure),
nd strongly with peak exercise oxygen consumption (VO2),
eak oxygen pulse, and minute ventilation–carbon dioxide
utput slope (VE-VCO2 slope) in IPAH. Arterial oxygen
esaturation 10% during the 6MWT increases mortality
isk 2.9 times over a median follow-up of 26 months (15).
Cardiopulmonary exercise testing is discussed in more detail
lsewhere in this Supplement. Consistent observations in
AH are reduced peak VO2, peak work rate, the ratio of VO2
ncrease to work rate increase, anaerobic threshold, peak
xygen pulse, and increased VE-VCO2 slope. These obser-
ations indicate that the mechanism(s) of exercise limita-
ions in PAH include V/Q mismatching, lactic acidosis at a
ow work rate, arterial hypoxemia, and inability to ade-
uately increase stroke volume and cardiac output (16).
Exercise Doppler echocardiography has been utilized to
valuate RVSP responses with exercise. In healthy men,
ricuspid regurgitant velocity increases from an average of
.72 m/s at baseline to a peak of 2.46 m/s at mid-level
xercise and to 2.27 m/s at peak exercise (240 W); in trained
thletes the baseline value is 2.25 m/s and increases to 3.41
/s at peak exercise (17). As with invasive exercise studies,
he criteria for an abnormal response are not well estab-
ished.
Right heart catheterization is required to confirm the
iagnosis of PAH. Cardiac output, determined by ther-
odilution or Fick (with measured oxygen consumption)
uring RHC is also required to calculate pulmonary vascular
esistance. Pulmonary arterial hypertension is defined by a
ean pulmonary artery pressure (mPAP) 25 mm Hg at
est or 30 mm Hg with exercise; in PAH, pulmonary
apillary wedge pressure or left ventricular end diastolic
ressure is 15 mm Hg and pulmonary vascular resistance
s 3 units. The RHC also characterizes intracardiac
hunting, and it establishes pulmonary venous pressure. An
levated pulmonary capillary wedge pressure supports the
resence of left heart disease or pulmonary vein obstruction,
hough a normal pulmonary capillary wedge pressure does
ot rule out pulmonary veno-occlusive disease.
Hemodynamic measurements have been used to estimate
he natural history of IPAH in an individual patient. The
robability of survival P(t) one, two, or three years after
iagnosis can be estimated as P(t)  {H(t)}A(x,y,z),
here H(t)  {0.88  0.14t  0.01t2}, A(x,y,z) 
(0.007325x  0.0526y  0.3275z), t  years, x  mPAP (mm
g), y  mRAP (mm Hg), and z  cardiac index (CI)
l/min/m2) (18). Other logistic regression equations have
een reported to predict survival or death within one year.
Importantly, a vasodilator study should be performed
henever PAH is discovered or confirmed during RHC in
atients in whom symptoms and/or disease severity warrant
reatment. All patients in whom vasodilator treatment is toe initiated require hemodynamic monitoring for detection
f either beneficial or detrimental effects of acute treatment.
ncontrolled studies have suggested that long-term admin-
stration of calcium-channel blockers (CCB) prolongs sur-
ival in the rare subset of responsive patients compared with
nresponsive patients. Unfortunately, no clinical or hemo-
ynamic parameters exist that can predict acute and/or
hronic responses to CCB in PAH patients. It is generally
ccepted that patients who may benefit from long-term
CB can be identified by an acute vasodilator challenge
erformed during RHC; that is, a sustained benefit from
CB treatment is seen in patients in whom, during acute
asodilator testing, mPAP decreases 10 mm Hg to reach
mPAP 40 mm Hg with a normal or high cardiac output
19). Owing to the potential risk of severe life-threatening
emodynamic compromise occurring with acute vasodilator
hallenge with CCB, acute vasodilator testing should be
one using a safe, potent, and short-acting vasodilator with
imited side effects to identify with accuracy those patients
ho may benefit from long-term CCB therapy.
The acute pulmonary effect of short-acting vasodilators
e.g., intravenous epoprostenol, inhaled nitric oxide [NO],
ntravenous adenosine, or inhaled iloprost) predicts the
emodynamic response to long-term CCB. Thus, the effi-
acy of the short-acting drug has been used to determine
hether chronic CCB treatment should be initiated. How-
ver, with novel oral and inhaled therapeutic agents com-
ining vasodilatory and antiproliferative properties now
vailable (e.g., endothelin receptor antagonists, prostacyclin
nalogues, and phosphodiesterase type 5 inhibitors), the
sefulness of invasive testing for pulmonary vasoreactivity in
electing optimal treatment is now less clear. Although it is
easonable to believe that patients who respond to intrave-
ous epoprostenol, inhaled NO, intravenous adenosine, or
nhaled iloprost will respond to such oral or inhaled thera-
ies, no study has evaluated the acute and chronic responses
o these drugs in vasoreactive patients.
The abrupt development of pulmonary edema during
cute vasodilator testing suggests the presence of pulmonary
eno-occlusive disease or pulmonary capillary hemangioma-
osis and is a contraindication to chronic vasodilator treat-
ent.
HARACTERIZATION: CONTINGENT TESTS
ertain tests are contingent on the presentation and results
f essential testing (Fig. 1). They may not be necessary in all
atients. Transesophageal echocardiography (TEE) provides
mportant data that may alter treatment in up to 25% of
atients. Useful in the detection of intracardiac shunts,
specially atrial septal defects, TEE can also detect central
ulmonary emboli including chronic thromboemboli caus-
ng PAH, with a reported sensitivity of 80% (20), and up to
6%, with a specificity of 88%, in patients with documented
evere central acute or chronic thromboembolism (21).
˙ ˙Additional imaging may be required if the V/Q scan is
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Evaluation of Pulmonary Arterial Hypertension June 16, 2004:40S–47Suggestive of chronic pulmonary embolism. Chest computer-
zed tomography (CT) provides supportive noninvasive evi-
ence, but if negative it should not obviate the use of
ulmonary angiography. A mosaic pattern of lung attenua-
ion in a noncontrast CT scan raises the possibility of
hronic thromboembolism. Contrast-enhanced spiral (or
elical) CT or electron-beam CT (EBCT) can visualize
entral chronic pulmonary thromboemboli. The CT fea-
ures of chronic thromboembolic disease are complete
cclusion of pulmonary arteries, eccentric filling defects
onsistent with thrombi, recanalization, and stenoses or
ebs.
The sensitivity of spiral CT for detecting central pulmo-
ary embolism is 85% to 90%. Though sensitivity for
etecting distal emboli is lower, detection rates of up to 97%
or distal emboli (compared with high probability V˙/Q˙
cans or angiography) have been reported (20). Specificity is
lso 90%, with occasional misclassification of IPAH as
eing CTEPH (20).
igure 2. (A) Long-term (7-year) survival in patients with idiopathic
ulmonary arterial hypertension (IPAH) based on functional class (III vs.
V) at the time of epoprostenol initiation. p 0.0001 by log-rank test (30).
B) Survival in patients with IPAH treated with intravenous epoprostenol
ccording to New York Heart Association (NYHA) functional class.
stimated percentages of survival for patients in NYHA functional class IV
t baseline (dashed line) were 76%, 60%, and 47% at one, two, and three
ears, respectively, as compared with 90%, 76%, and 71% for patients in
YHA functional class III at baseline (solid line) (p  0.001 by the
ox-Mantel log-rank test) (32).The EBCT signs of pulmonary vein obstruction (e.g., lulmonary veno-occlusive disease) are smooth thickening of
nterlobular septa, peribronchovascular cuffing, and alveolar
round-glass opacification.
High-resolution CT provides detailed views of the lung
arenchyma during evaluation of PH or hypoxia and aids in
he diagnosis of pulmonary fibrosis. Diffuse bilateral thick-
ning of the interlobular septae and the presence of small,
entrilobular, poorly circumscribed nodular opacities sug-
est pulmonary capillary hemangiomatosis; diffuse central
round-glass opacification and thickening of interolobular
epta suggest pulmonary veno-occlusive disease.
Pulmonary angiography is required to confirm CTEPH
nd assess operability. Chronic thrombi appear different
rom acute thrombi and occur in highly variable locations,
ften incorporated into and retracting the vessel wall.
bstructions can take the form of bands or webs, sometimes
ith post-stenotic dilation. Irregular intimal surface,
ounded or pouch-like termination of segmental branches,
igure 3. (A) Subsequent survival in patients with idiopathic pulmonary
rterial hypertension (IPAH) stratified by functional class after 1 year
poprostenal treatment 1: p  0.001 for functional class III vs. functional
lass IV and for functional class III vs. functional class I and functional class
I (30). (B) Survival in patients with IPAH treated with intravenous
poprostenol according to New York Heart Association (NYHA) func-
ional class. After three months of treatment with epoprostenol, survival
ates for patients reclassified in NYHA functional class I or II (solid line)
ere 100%, 93%, and 88% at one, two, and three years, respectively, as
ompared with 77%, 46%, and 33% for patients persisting in NYHA
unctional class III or IV (dashed line) (p  0.001 by the Cox-Mantel
og-rank test) (32).uminal narrowing of the central vessel, and odd-shaped
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June 16, 2004:40S–47S Evaluation of Pulmonary Arterial Hypertensionulmonary arteries all may indicate the presence of chronic
ulmonary embolism.
For patients with known or suspected CTEPH, further
valuation of a potential clotting diathesis is warranted
bleeding time, coagulation Factors VIII, VII, II, and V,
on Willebrand factors, Protein C and S). Factor V Leiden
utation (the most common cause of activated protein C
esistance) has been implicated as high risk for idiopathic
enous thromboembolism, though not specifically in pul-
onary embolism or CTEPH. Serum viscosity, serum
rotein electrophoresis, and Hgb electrophoresis may be
elpful under certain circumstances.
Additional blood tests may provide prognostic data. Arterial
lood gas or oximetry measurements showing desaturation
ay signal abnormal gas exchange, right-to-left shunting,
entilation/perfusion mismatching, interstitial fibrosis,
ther parenchymal lung disease, or hypoventilation. Failure
o normalize with high FiO2 oxygen inhalation supports a
omponent of right-to-left shunting. Arterial blood gas
igure 4. (A) Kaplan-Meier survival estimates in 156 patients with
diopathic pulmonary arterial hypertension (IPAH), according to the
esults of the 6-min walk (6MW) test performed after three months of
poprostenol therapy. Survival rates for patients walking 380 m during
he 6MW test (corresponding to the median value) (solid line) were 99%,
8%, and 81% at one, two, and three years, respectively, as compared with
6%, 64%, and 56% for patients walking 380 m (dashed line) (p 
.0005 by the Cox-Mantel log-rank test). (B) Kaplan-Meier survival
stimates in 156 patients with IPAH, according to the change in the
MWT between baseline and three months of epoprostenol therapy. No
ifference in survival was demonstrated in patients who improved their
-min walk distance to112 m (corresponding to the median value) (solid
ine), as compared with those who did not (dashed line) (p  0.86 by the
ox-Mantel log-rank test) (32).easurement or oximetry during exercise may disclose lesaturation requiring supplemental oxygen treatment to
mprove exercise capacity. Overnight oximetry may disclose
isordered sleep with frequent desaturations and may be the
rst clue to sleep apnea sufficient to cause or contribute to
H. Nocturnal hypoxemia occurs in 75% of IPAH
atients independent of the occurrence of apneas or hypop-
eas (22).
Hyperuricemia occurs with high frequency in patients with
H and correlates with hemodynamic abnormalities (e.g.,
ight atrial pressure) and mortality in IPAH (23).
Brain natriuretic peptide (BNP) is elevated in right ven-
ricular pressure overload and correlates with severity of
ight ventricular dysfunction and mortality in PAH (24).
If the history and/or screening overnight oximetry is
uggestive, polysomnography should be considered to assess a
ossible contributory role in PH. Up to 20% to 27% of
atients with sleep apnea syndromes have PH (25). The
egree of waking PH in obstructive sleep apnea is generally
ild and reversible by six months of continuous positive
irway pressures, i.e., CPAP (26). Open or thoracoscopic
ung biopsy entails substantial risk of morbidity and mortal-
ty. Because of the low likelihood of altering the diagnosis,
outine biopsy is discouraged. Under certain circumstances,
istopathologic findings may provide useful information by
xcluding or establishing a diagnosis of active vasculitis,
ranulomatous pulmonary disease, pulmonary veno-
cclusive disease, pulmonary capillary hemangiomatosis,
nterstitial lung disease, or bronchiolitis (27).
SSESSMENT OF PAH SEVERITY
fter PAH is diagnosed, in order to assess risk:benefit
rofiles for various therapeutic options accurately, precise
ssessment of prognosis as a function of disease severity is
equired. Measurable descriptors of disease severity have
everal potential applications: 1) accurate comparison of
atient populations, 2) precise characterization of a patient
opulation for the purpose of homogeneous enrollment into
linical protocols, 3) valid comparison of baseline severity
ith post-treatment severity as a measurement of therapeu-
ic efficacy, 4) valid comparison of post-treatment severity of
imilar patients on alternative treatment strategies, 5) accu-
ate longevity prediction (or surrogate for survival in clinical
tudies), and 6) useful early prediction for timing of trans-
lantation. The characteristics of ideal descriptor(s) of
isease severity include: 1) easily performed assessment
rocedure, 2) reproducible results temporally and between
enters, 3) high correlation with outcome of interest (e.g.,
urvival), 4) low risk, 5) low expense, 6) low discomfort
evel, and 7) wide availability.
Various demographic and hemodynamic characteristics,
s well as exercise capacity, acute pulmonary vasoreactivity,
ssessment of right ventricular function, neurohormonal
evels (e.g., BNP [24], norepinephrine [28]), as well as
ndothelin-1 (29), uric acid (23), and troponin (31), corre-
ate with survival. Some of these modalities may provide
p
t
u
t
c
s
w
o
r
t
r
p
T
p
o
c
p
P
h
p
f
d
t
c
e
b
e
t
p
n
n
1
e
6
m
I
p
p
n
i
d
a
e
p
p
s
m
r
1
s
d
o
c
R
C
1
E
R
1
1
1
1
1
1
1
1
1
1
46S Barst et al. JACC Vol. 43, No. 12 Suppl S
Evaluation of Pulmonary Arterial Hypertension June 16, 2004:40S–47Srognostic information similar to that derived from invasive
ests (e.g., cardiac catheterization) and may prove more
seful and convenient in assessing treatment efficacy. These
ools may also increase predictive accuracy when used in
ombination. Because many of these variables have been
hown to correlate with one another, which parameter(s)
ill prove to be most useful for decision making and
ptimizing treatment (e.g., timing of transplantation) will
equire further study. It is important to remember that these
ests evaluated IPAH patients and not patients with PAH
elated to connective tissue disorders, congenital systemic to
ulmonary shunts, HIV infection, or portal hypertension.
hus, these parameters must be applied cautiously to PAH
atients in whom comorbid factors might contribute to the
verall outcome; for example, patients with PAH related to
onnective tissue disorders are known to have a worse
rognosis than do IPAH patients, whereas patients with
AH related to congenital systemic to pulmonary shunts
ave a more slowly progressive course than do IPAH
atients.
In addition to evaluating various parameters, such as
unctional class (32) or exercise capacity, at the time of
iagnosis prior to initiation of medical therapy, repeating
hese parameters on treatment is useful in predicting out-
ome with a given therapy (e.g., epoprostenol). McLaughlin
t al. (30) as well as Sitbon et al. (32) demonstrated that the
aseline functional class in patients with IPAH treated with
poprostenol (i.e., before epoprostenol is started) is predic-
ive of survival with epoprostenol (Fig. 2). In addition,
atients’ functional class on chronic intravenous epoproste-
ol is also predictive of outcome with continued epoproste-
ol (Fig. 3) (30,32). Additional survival parameters include:
) right atrial size and pericardial effusion assessed by
chocardiography; 2) exercise endurance assessed by the
MWT, both at the time of diagnosis as well as on chronic
edical therapy (e.g., epoprostenol); and 3) hemodynamics.
t appears that although the baseline 6-min walk distance
rior to epoprostenol treatment is useful as a parameter in
redicting disease severity, once a patient is on epoproste-
ol, the actual 6-min walk distance on chronic epoprostenol
s more predictive of survival than the change in 6-min walk
istance with epoprostenol (Fig. 4) (32). By multivariate
nalysis in IPAH patients treated with epoprostenol, Sitbon
t al. (32) reported that the only parameter independently
redictive of outcome prior to starting epoprostenol is the
resence of right heart failure; after three months of epopro-
tenol, persistence of functional class III or IV, mPAP 59
m Hg and a drop in pulmonary vascular resistance 30%
elative to baseline are associated with a poor prognosis.
In conclusion, evaluating disease severity as a function of:
) end-organ consequences (e.g., right heart failure), 2)
ymptoms and functional limitation, and 3) markers of
ecreased survival is necessary for decision making to
ptimize the appropriate aggressiveness of PAH patients’
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